Jeffrey S. Dome

ORCID: 0000-0002-9037-369X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal and related cancers
  • Renal cell carcinoma treatment
  • Ethics and Legal Issues in Pediatric Healthcare
  • Childhood Cancer Survivors' Quality of Life
  • Telomeres, Telomerase, and Senescence
  • Tumors and Oncological Cases
  • Sarcoma Diagnosis and Treatment
  • Radiation Therapy and Dosimetry
  • Neuroblastoma Research and Treatments
  • Urological Disorders and Treatments
  • Pediatric Urology and Nephrology Studies
  • Pharmaceutical studies and practices
  • Viral gastroenteritis research and epidemiology
  • Prenatal Screening and Diagnostics
  • Cancer Genomics and Diagnostics
  • Virus-based gene therapy research
  • Chromatin Remodeling and Cancer
  • Pancreatic and Hepatic Oncology Research
  • Cancer Research and Treatments
  • Congenital Diaphragmatic Hernia Studies
  • CAR-T cell therapy research
  • Epigenetics and DNA Methylation
  • DNA Repair Mechanisms
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery

George Washington University
2014-2025

Center for Cancer and Blood Disorders
2010-2025

Children's National
2015-2024

George Washington University Hospital
2020-2024

University of Southern California
2006-2020

Cincinnati Children's Hospital Medical Center
2011-2019

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2017-2019

St. Jude Children's Research Hospital
2004-2018

British Columbia Children's Hospital
2018

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2006-2018

An objective of the fifth National Wilms' Tumor Study (NWTS-5) was to evaluate efficacy treatment regimens for anaplastic histology tumor (AH).Prospective single-arm studies were conducted. Patients with stage I AH treated vincristine and dactinomycin 18 weeks. stages II IV diffuse vincristine, doxorubicin, cyclophosphamide, etoposide 24 weeks plus flank/abdominal radiation.A total 2,596 patients enrolled onto NWTS-5, whom 281 (10.8%) had AH. Four-year event-free survival (EFS) overall (OS)...

10.1200/jco.2005.04.7852 article EN Journal of Clinical Oncology 2006-05-18

The pathogenesis of cystic nephroma the kidney has interested pathologists for over 50 years. Emerging from its initial designation as a type unilateral multilocular cyst, been considered either developmental abnormality or neoplasm both. Many have viewed benign end pathologic spectrum with partially differentiated nephroblastoma and Wilms tumor, whereas others it mixed epithelial stromal tumor. We hypothesize that nephroma, like pleuropulmonary blastoma in lung, represents abnormal renal...

10.1038/modpathol.2013.242 article EN cc-by-nc-sa Modern Pathology 2014-01-31

The objective of this study is to determine prognostic factors in rhabdoid tumor the kidney (RTK), including both demographic and treatment variables.A total 142 patients studied on National Wilms' Tumor Studies 1, 2, 3, 4, 5 were analyzed. Patients enrolled between years 1969 2002. Variables examined included sex, age diagnosis, stage, presence CNS lesions, as well variables, use doxorubicin and/or radiotherapy (RT).No survival differences observed males females, those treated with or...

10.1200/jco.2004.00.8110 article EN Journal of Clinical Oncology 2005-10-18

Increasing evidence suggests that chromosomal regions containing microRNAs are functionally important in cancers. Here, we show genomic loci encoding miR-204 frequently lost multiple cancers, including ovarian pediatric renal tumors, and breast MiR-204 shows drastically reduced expression several cancers acts as a potent tumor suppressor, inhibiting metastasis vivo when systemically delivered. We demonstrated exerts its function by targeting genes involved tumorigenesis brain-derived...

10.1371/journal.pone.0052397 article EN cc-by PLoS ONE 2012-12-21

Purpose The goal of this study was to analyze the association copy number gain 1q in favorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall (OS) within each tumor stage 1p 16q loss and/or heterozygosity. Methods Unilateral FHWTs from 1,114 patients enrolled National Tumor Study-5 that were informative for microsatellite markers (previously determined) gain, loss, using multiplex ligation-dependent probe amplification analyzed. Results Eight-year EFS 86% (95% CI,...

10.1200/jco.2015.66.1140 article EN Journal of Clinical Oncology 2016-07-12

Wilms tumors (WT) have provided broad insights into the interface between development and tumorigenesis. Further understanding is confounded by their genetic, histologic, clinical heterogeneity, basis of which remains largely unknown. We evaluated 224 WT for global gene expression patterns; WT1, CTNNB1, WTX mutation; 11p15 copy number methylation patterns. Five subsets were identified showing distinct differences in pathologic features: these findings validated 100 additional WT. The pattern...

10.1593/neo.12714 article EN cc-by-nc-nd Neoplasia 2012-08-01

Purpose The National Wilms Tumor Study (NWTS) treatment of favorable histology tumor with lung metastases was vincristine/dactinomycin/doxorubicin (DD4A) and radiation therapy (RT). AREN0533 study applied a new risk stratification strategy to improve event-free survival (EFS) while reducing exposure RT. Methods Patients isolated showing complete nodule response (CR) after 6 weeks DD4A continued receiving chemotherapy without incomplete (IR) or loss heterozygosity at chromosomes 1p/16q...

10.1200/jco.2017.77.1931 article EN Journal of Clinical Oncology 2018-04-16

BACKGROUND The current study was conducted to characterize the epidemiology, histology, and radiographic features of as well surgical approach pediatric adolescent renal cell carcinoma (pRCC). METHODS pRCC cases prospectively enrolled on Children's Oncology Group AREN03B2 underwent central pathology, radiology, surgery, oncology review. RESULTS As June 2012, 120 a total 3250 patients (3.7%) were found have unilateral RCC (median age, 12.9 years [range, 1.9‐22.1 years]; 52.5% female). Central...

10.1002/cncr.29368 article EN Cancer 2015-04-06

Abstract Purpose: To investigate the role and significance of TP53 mutation in diffusely anaplastic Wilms tumors (DAWTs). Experimental Design: All DAWTs registered on National Tumor Study-5 (n = 118) with available samples were analyzed for mutations copy loss. Integrative genomic analysis was performed 39 selected DAWTs. Results: Following a single random sample, 57 (48%) demonstrated mutations, 13 (11%) loss without mutation, 48 (41%) lacked both [defined as TP53-wild-type (wt)]. Patients...

10.1158/1078-0432.ccr-16-0985 article EN Clinical Cancer Research 2016-10-05

Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) radiation therapy. Further risk stratification required improve outcomes reduce late effects. We evaluated clinical biologic variables for patients with FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p 16q treated in the Children’s Oncology Group protocol AREN0532. Methods From October 2006 August...

10.1200/jco.2017.73.7999 article EN Journal of Clinical Oncology 2017-12-06

To determine if observation alone after nephrectomy in very low-risk Wilms tumor (defined as stage I favorable histology tumors with weight <550g and age at diagnosis <2 years) results satisfactory event-free survival overall survival, to correlate relapse biomarkers.The AREN0532 study enrolled patients confirmed by central review of pathology, diagnostic imaging, surgical reports. After nephrectomy, were followed without adjuvant chemotherapy. Evaluable analyzed for WT1mutation, 1p 16q copy...

10.1097/sla.0000000000001716 article EN Annals of Surgery 2016-11-03

BACKGROUND Renal cell carcinomas (RCCs) are rare in young patients. Knowledge of their pathologic and molecular spectrum remains limited, no prospective studies have been performed to date this population. This study analyzes patients diagnosed with RCC who were prospectively enrolled the AREN03B2 Children's Oncology Group (COG). The objective was classify these tumors aid focused genetic testing characterize features. METHODS All registered as by central review retrospectively re‐reviewed...

10.1002/cncr.31578 article EN cc-by Cancer 2018-06-15

AREN0321 evaluated the activity of vincristine and irinotecan (VI) in patients with newly diagnosed diffuse anaplastic Wilms tumor (DAWT) whether a regimen containing carboplatin (regimen UH1) addition to I agents used National Tumor Study 5 (NWTS-5; vincristine, doxorubicin, cyclophosphamide, etoposide plus radiotherapy) would improve patient outcomes.Patients stage II IV DAWT without measurable disease received UH1. Patients were eligible receive VI (vincristine, 1.5 mg/m2 per day...

10.1200/jco.19.01265 article EN Journal of Clinical Oncology 2020-03-05

Summary. To create immortal mesenchymal cell lines, we transduced primary human bone marrow cells with telomerase reverse transcriptase (TERT). TERT + continued to grow for &gt; 2 years; parallel – cultures underwent senescence after 15 weeks. did not form foci in soft agar, had a normal karyotype and could differentiate into osteoblasts chondrocytes. Their capacity support leukaemic lymphoblasts CD34 haematopoietic was equal or greater than that of cells; 42 clones varied their supporting...

10.1046/j.1365-2141.2003.04217.x article EN British Journal of Haematology 2003-03-01

Approximately 5% of children with Wilms tumor present bilateral disease. The treatment challenge is to achieve a high cure rate while maintaining adequate long-term renal function. authors this report assessed the feasibility and outcome nephron-sparing surgery in patients who were treated at single institution.A retrospective review was performed all St. Jude Children's Research Hospital for synchronous, tumors from 1999 through 2006. Imaging studies, surgical techniques, pathology reports...

10.1002/cncr.23406 article EN Cancer 2008-03-24
Coming Soon ...